论文部分内容阅读
目的：确定硒酸酯多糖（κ硒卡拉胶）临床应用价值。方法：采用多中心随机分组双盲临床试验，观察恢复期和化、放疗患者口服硒酸酯多糖（治疗组）与安慰剂（对照组）对免疫功能的影响。结果：在恢复期患者，治疗组Ｔ４细胞从疗前（３３．６９±９．８６）％升至（３９．７８±９．６６）％（Ｐ＜０．０５），Ｔ４／Ｔ８比值从１．１９±０．３７升至１．３９±０．３７（Ｐ＜０．０１）；而对照组Ｔ４、Ｔ８及Ｔ４／Ｔ８比值均无显著变化（Ｐ＞０．０５）。治疗组患者ＰＰＤ试验反应增强者为５１．０％，对照组仅为２３．１％（Ｐ＜０．０５）。在化、放疗患者，治疗组Ｔ４细胞从（３３．８１±７．３０）％升至（３５．４２±７．６６）％（Ｐ＜０．０５），Ｔ４／Ｔ８从１．２２±０．３２升至１．３６±０．３８（Ｐ＜０．０１），Ｔ８细胞则从（２９．０３±８．９０）％降至（２７．４７±７．６２）％（Ｐ＜０．０１）；对照组Ｔ４／Ｔ８比值从１．２５±０．５５降至１．１５±０．３６（Ｐ＜０．０５）。治疗组与对照组ＰＰＤ试验反应增强者分别为３５．６％与１５．７％（Ｐ＜０．００１）。另外，治疗组患者巨噬细胞吞噬率、血清ＩｇＧ、ＩｇＡ均明显上升，而对照组则明显下降。两组患者Ｎ?
Objective: To determine the clinical application of selenate polysaccharide (κ-selenium carrageenan). Methods: A multicenter, randomized, double-blind clinical trial was conducted to observe the effect of oral administration of selenite polysaccharide (placebo) and placebo (placebo) on immune function in patients undergoing convalescent and chemoradiotherapy. Results: During the recovery period, the T4 cells in treatment group increased from (33.69 ± 9.86)% to (39.78 ± 9.66)% (P <0.05), and T4 / T8 ratio increased from 1 .19 ± 0.37 to 1.39 ± 0.37 (P <0.01), while there was no significant change in the ratio of T4, T8 and T4 / T8 in the control group (P> 0.05). In the treatment group, the response to PPD test was 51.0% and that of the control group was only 23.1% (P <0.05). The number of T4 cells increased from (33.81 ± 7.30)% to (35.42 ± 7.66)% (P <0.05), and the ratio of T4 / T8 increased from 1.22 ± 0 .32 increased to 1.36 ± 0.38 (P <0.01), while T8 cells decreased from (29.03 ± 8.90)% to (27.47 ± 7.62)% (P <0. 01). The ratio of T4 / T8 in control group decreased from 1.25 ± 0.55 to 1.15 ± 0.36 (P <0.05). The responders to the PPD test in the treatment group and control group were 35.6% and 15.7%, respectively (P <0.001). In addition, macrophage phagocytosis rate, serum IgG, IgA were significantly increased in treatment group, while the control group was significantly decreased. Two groups of patients N?